If a charity organization collected billions of dollars with little evidence that needy people benefited, regulators and the public would quickly demand answers.
Yet many large hospital systems participating in the federal 340B Drug Pricing Program are quietly doing just that—extracting billions in drug discounts with scarce oversight and no obligation to prove vulnerable patients benefit.
That should alarm anyone concerned about rising healthcare costs, misuse of taxpayer dollars, financial burdens on employers, or the integrity of our nation’s safety net. Congress must stop ignoring this problem and inject some badly needed transparency into 340B.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
It’s Time For Congress To Get 340B Out Of Its Blind Spot
Sally C. Pipes
If a charity organization collected billions of dollars with little evidence that needy people benefited, regulators and the public would quickly demand answers.
Yet many large hospital systems participating in the federal 340B Drug Pricing Program are quietly doing just that—extracting billions in drug discounts with scarce oversight and no obligation to prove vulnerable patients benefit.
That should alarm anyone concerned about rising healthcare costs, misuse of taxpayer dollars, financial burdens on employers, or the integrity of our nation’s safety net. Congress must stop ignoring this problem and inject some badly needed transparency into 340B.
Read the full article at Forbes
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.